Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Pivya (Pivmecillinam) is indicated for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (uUTI) caused by susceptible isolates of Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus.
• This summary is based on the review of one randomized controlled trial(s). ^[1]
• Symptomatic Resolution by Day 4: Pivmecillinam achieved symptomatic resolution in 73.6% of patients by day 4, compared to 38.7% with ibuprofen, with a risk difference of 35% favoring pivmecillinam (90% CI: 27% to 43%).
• Secondary Outcomes - Antibiotic Treatment and Pyelonephritis: Pivmecillinam showed more favorable outcomes in reducing the need for secondary antibiotic treatment. All 7 cases of pyelonephritis occurred in the ibuprofen group.
• There is no safety information available in the reviewed studies.
• The study focuses on non-pregnant women aged 18-60 years with symptoms of uncomplicated UTI in Norway, Sweden, and Denmark, noting that extensive exclusion criteria and the lack of symptom registration for non-participants may limit the generalizability of the findings.